Nirav N. Shah, MD, discusses bispecific anti-CD20 and anti-CD19 chimeric antigen receptor T cells in a phase 1 dose escalation and expansion trial for relapsed B cell malignancies.
Nirav N. Shah, MD, an associate professor at the Medical College of Wisconsin, discusses bispecific anti-CD20 and anti-CD19 chimeric antigen receptor (CAR) T cells in a phase 1 dose escalation and expansion trial (NCT03019055) for relapsed B cell malignancies.
There was not a lot of toxicity with the CAR T treatment, and rates of cytokine release syndrome and neurotoxicity were low, according to Shah. The first 6 patients on the study were able to start on the target dose level. These patients demonstrated a high response rate.
The manufacturing of the treatment for this trial was done in-house using the CliniMACS Prodigy device, which allows for point-of-care manufacturing. Shah says this allowed…